市場調查報告書

全身型重症肌無力(gMG):2028年前的流行病學預測

Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 905937
出版日期 內容資訊 英文 87 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身型重症肌無力(gMG):2028年前的流行病學預測 Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028
出版日期: 2019年08月01日內容資訊: 英文 87 Pages
簡介

本報告提供全球全身型重症肌無力(gMG)的相關調查,提供疾病概要,MGFA分類,患者人口,美國·德國·法國·義大利·西班牙·英國·日本等主要7個國家的流行病學等資訊。

目錄

第1章 重要的洞察

第2章 全身型重症肌無力:流行病學概要

  • 患者佔有率(%)2017年的分佈
  • 患者佔有率(%)2028年的分佈

第3章 疾病概要:全身型重症肌無力

  • 簡介
  • 重症肌無力的種類
    • 眼部重症肌無力
    • 全身型重症肌無力
  • 重症肌無力的MGFA分類
  • 病因
  • 危險因素
  • 徵兆及症狀
  • MG的合併症
  • 遺傳的根據
  • 病理生理學
    • 自我抗體
    • 補數連鎖
  • 生物標記
  • 診斷
    • 鑑別診斷
    • 日本的診斷標準

第4章 流行病學及患者人口

  • 主要調查結果
  • 人口及預測參數
  • 主要7個國家的整體患者數
  • 各國流行病學
  • 美國
    • 假設及根據
    • 美國的整體診斷案例
    • 自我抗體-美國的全身性重症肌無力的具體案例
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 市場成長要素

第6章 市場障礙

第7章 附錄

第8章 報告方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

第12章 免責聲明

目錄
Product Code: DIEI0369

DelveInsight's 'Generalized Myasthenia Gravis (gMG)-Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Generalized Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Generalized Myasthenia Gravis Epidemiology

The Generalized Myasthenia Gravis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Generalized Myasthenia Gravis are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Generalized Myasthenia Gravis Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The epidemiology is segmented by total diagnosed prevalent cases and auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2028.

According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017.

Report Scope

  • The report covers a detailed overview of Generalized Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by auto-antibodies-specific cases of Generalized Myasthenia Gravis in 7MM.

Key strengths

  • 10 Year Forecast of Generalized Myasthenia Gravis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Generalized Myasthenia Gravis
  • Prevalent Cases according to segmentation: auto-antibodies specific cases

Key assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Generalized Myasthenia Gravis: Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of gMG in 2017
  • 2.2. Patient Share (%) Distribution of gMG in 2028

3. Disease Overview: Generalized Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Types of Myasthenia Gravis
    • 3.2.1. Ocular Myasthenia Gravis
    • 3.2.2. Generalized Myasthenia Gravis
  • 3.3. MGFA Classification of Myasthenia Gravis
  • 3.4. Etiology
  • 3.5. Risk Factors
  • 3.6. Signs and Symptoms
  • 3.7. Comorbid conditions in MG
  • 3.8. Genetic Basis of Generalized Myasthenia Gravis
  • 3.9. Pathophysiology of Generalized Myasthenia Gravis
    • 3.9.1. Autoantibodies
    • 3.9.2. Complement cascade
  • 3.10. Biomarkers in Generalized Myasthenia Gravis
  • 3.11. Diagnosis
    • 3.11.1. Differential Diagnosis
    • 3.11.2. Japanese diagnostic criteria for Myasthenia Gravis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis
  • 4.4. Country Wise-Epidemiology of Myasthenia Gravis
  • 4.5. United States
    • 4.5.1. Assumptions and Rationale
    • 4.5.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the US
    • 4.5.3. Autoantibodies- Specific Cases of Generalized Myasthenia Gravis in the US
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Germany
    • 4.6.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in France
    • 4.7.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Italy
    • 4.8.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Spain
    • 4.9.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the United Kingdom
    • 4.10.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan
    • 4.11.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Japan

5. Market Drivers

6. Market Barriers

7. Appendix

8. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Disclaimer

List of Tables

  • Table 1: Osserman and Genkins Classification of Myasthenia Gravis, modified by the MGFA/Task Force
  • Table 2: Summary of the tests used in the diagnosis of myasthenia gravis
  • Table 3: Proposed diagnostic criteria for myasthenia gravis - Japanese Treatment guidelines
  • Table 4: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Table 5: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Table 6: Autoantibodies specific cases of Myasthenia Gravis in the United States (2017-2028)
  • Table 7: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 8: Autoantibodies specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 9: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 10: Autoantibodies specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 11: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 12: Autoantibodies specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 13: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 14: Autoantibodies specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 15: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 16: Autoantibodies specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 17: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Table 18: Autoantibodies specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)

List of Figures

  • Figure 1: Transmission of Nerve Impulses to Muscles
  • Figure 2: Signs and Symptoms of Generalized Myasthenia Gravis
  • Figure 3: Various Components of the Neuromuscular Junction involved in MG
  • Figure 4: Various Components of the Neuromuscular Junction involved in MG
  • Figure 5: Pathophysiology of MG at the neuromuscular junction
  • Figure 6: Complement cascade
  • Figure 7: Diagnostic testing in myasthenia gravis
  • Figure 8: Diagnosis flowchart for MG
  • Figure 9: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Figure 10: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Figure 11: Autoantibodies-specific cases of Myasthenia Gravis in the US (2017-2028)
  • Figure 12: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 13: Autoantibodies specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 14: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 15: Autoantibodies specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 17: Autoantibodies specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 18: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 19: Autoantibodies specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 20: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 21: Autoantibodies specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 22: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 23: Autoantibodies specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 24: Unmet needs
  • Figure 25: Market Drivers
  • Figure 23: Market Barriers
Back to Top